Filing Flows › Companies › Atrium Therapeutics › Cash flow
Atrium Therapeutics cash flow, quarter by quarter
Latest: Q2 2026 · from the cash-flow statements filed with the SEC
Free cash flow−$4.0M in Q2 2026
Analysis
In Q2 2026, Atrium Therapeutics generated −$3.9M of operating cash flow and spent $36K on capital projects, leaving free cash flow of −$4.0M. That is $8.2M more than in Q2 2025 (−$12.2M).
Operating cash flow was −$3.9M against net income of −$20.2M. The largest differences: accrued liabilities +$6.3M, deferred revenue −$3.0M, payables +$2.7M.
Free cash flow
Where the cash came from and went
From profit to cash
Every quarter
| Quarter | Operating cash flow | Capital spending | Cash drawn (+) / kept (−) | Free cash flow |
|---|---|---|---|---|
| Q2 2026 | −$3.9M | −$36K | $196M | −$4.0M |
| Q1 2026 | −$31.1M | −$2.1M | −$268M | −$33.2M |
| Q2 2025 | −$11.9M | −$266K | — | −$12.2M |
| Q1 2025 | −$11.1M | — | — | −$11.1M |
Atrium Therapeutics: income statement and cash flow
Atrium Therapeutics, Q2 2026: revenue $3.0M (-22% year over year), operating margin -752.9%. The chart follows the revenue to costs, profit and cash.
Atrium Therapeutics: every quarter, Q/Q and Y/Y → Open in the app
Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.